These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28831945)

  • 1. Studies in vitro on infectivity and sensitivity to antileishmanial drugs in New World Leishmania species transfected with the green fluorescent protein [pIR3(-)-eGFP].
    Palacios G; Parodi A; Upegui YA; Montoya A; Pulido S; Vélez ID; Robledo SM
    Parasitology; 2017 Nov; 144(13):1718-1725. PubMed ID: 28831945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs.
    Pulido SA; Muñoz DL; Restrepo AM; Mesa CV; Alzate JF; Vélez ID; Robledo SM
    Acta Trop; 2012 Apr; 122(1):36-45. PubMed ID: 22155571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-commercial approach for the generation of transgenic Leishmania tarentolae and its application in antileishmanial drug discovery.
    Pineda T; Valencia Y; Flórez MF; Pulido SA; Vélez ID; Robledo SM
    Parasitology; 2016 Aug; 143(9):1133-42. PubMed ID: 27174193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein.
    Rocha MN; Corrêa CM; Melo MN; Beverley SM; Martins-Filho OA; Madureira AP; Soares RP
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):282-91. PubMed ID: 23312610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
    Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
    PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
    Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
    Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species.
    de Morais-Teixeira E; Gallupo MK; Rodrigues LF; Romanha AJ; Rabello A
    J Antimicrob Chemother; 2014 Jan; 69(1):150-4. PubMed ID: 23970484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.
    Fernández O; Diaz-Toro Y; Valderrama L; Ovalle C; Valderrama M; Castillo H; Perez M; Saravia NG
    J Clin Microbiol; 2012 Jul; 50(7):2207-11. PubMed ID: 22518860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug.
    Varela M RE; Muñoz DL; Robledo SM; Kolli BK; Dutta S; Chang KP; Muskus C
    Exp Parasitol; 2009 Jun; 122(2):134-9. PubMed ID: 19303871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis.
    Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J
    Rev Inst Med Trop Sao Paulo; 2007; 49(4):257-60. PubMed ID: 17823757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
    Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
    Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G; Foglia Manzillo V; Pagano A
    Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.
    Sadeghi S; Seyed N; Etemadzadeh MH; Abediankenari S; Rafati S; Taheri T
    Korean J Parasitol; 2015 Aug; 53(4):385-94. PubMed ID: 26323836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
    Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
    Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents.
    Taylor VM; Muñoz DL; Cedeño DL; Vélez ID; Jones MA; Robledo SM
    Exp Parasitol; 2010 Dec; 126(4):471-5. PubMed ID: 20685203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of nicotinamide/antileishmanial drug combinations.
    Gazanion E; Vergnes B; Seveno M; Garcia D; Oury B; Ait-Oudhia K; Ouaissi A; Sereno D
    Parasitol Int; 2011 Jan; 60(1):19-24. PubMed ID: 20884376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial activity of lapachol analogues.
    Lima NM; Correia CS; Leon LL; Machado GM; Madeira Mde F; Santana AE; Goulart MO
    Mem Inst Oswaldo Cruz; 2004 Nov; 99(7):757-61. PubMed ID: 15654435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.